Diosgenin

• Identification
• Experimental evidence
• Physicochemical properties
• ADMET properties
• Descriptors
• Chemical-gene interaction
• Chemical-phenotype interaction
• Chemical-disease association
• ToxCast endpoints
• Associated AOPs
• Presence in consumer products
• Presence in chemical regulation or guideline
• Presence in human biospecimen

Literature identifier	Study type	Test dosage	Effective dosage	Endocrine-mediated endpoints	Systems-level perturbations
PMID:37146712	IVR	1 - 8 mg/kg	1 - 8 mg/kg	Increased testis weights	Reproductive endocrine-mediated perturbations
	IVR	1 - 8 mg/kg	1 - 8 mg/kg	Increased Alkaline phosphatase (ALP) levels	Hepatic endocrine-mediated perturbations
	IVR	1 - 8 mg/kg	1 - 8 mg/kg	Increased Alanine aminotransferase (ALT) levels	Hepatic endocrine-mediated perturbations
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Oxidative stress in testis	Reproductive endocrine-mediated perturbations
	IVR	1 - 8 mg/kg	1 - 8 mg/kg	Increased cholesterol levels	Metabolic endocrine-mediated perturbations
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Induce apoptosis in testis	Reproductive endocrine-mediated perturbations
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Induce testicular damage	Reproductive endocrine-mediated perturbations
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Decreased testosterone levels	Reproductive endocrine-mediated perturbations
	IVR	1 - 2 mg/kg	1 - 2 mg/kg	Increased AST/ALT ratio	Hepatic endocrine-mediated perturbations
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Decreased uterine weights	Reproductive endocrine-mediated perturbations
	IVR	1 - 8 mg/kg	1 - 8 mg/kg	Increased triglycerides level	Metabolic endocrine-mediated perturbations
	IVR	1 - 8 mg/kg	1 - 8 mg/kg	Decreased ovarian weights	Reproductive endocrine-mediated perturbations
	IVR	1 - 8 mg/kg	1 - 8 mg/kg	Decreased HDL levels	Metabolic endocrine-mediated perturbations
	IVR	1 - 8 mg/kg	1 - 8 mg/kg	Increased LDL levels	Metabolic endocrine-mediated perturbations
	IVR	1 - 8 mg/kg	1 - 8 mg/kg	Increased Aspartate aminotransferase (AST) level	Hepatic endocrine-mediated perturbations
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Changes in ovarian morphology	Reproductive endocrine-mediated perturbations
	IVR	1 - 8 mg/kg	1 - 8 mg/kg	Decreased prostate weights	Reproductive endocrine-mediated perturbations
	IVR	1 - 8 mg/kg	1 - 8 mg/kg	Decreased testis weights	Reproductive endocrine-mediated perturbations
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Abnormal sperm morphology	Reproductive endocrine-mediated perturbations
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Reduced sperm counts	Reproductive endocrine-mediated perturbations
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Decreased LH levels	Reproductive endocrine-mediated perturbations
	IVR	1 - 8 mg/kg	1 - 8 mg/kg	Decreased body weights	Metabolic endocrine-mediated perturbations
	IVR	1 - 2 mg/kg	1 - 2 mg/kg	Increased estradiol levels	Reproductive endocrine-mediated perturbations
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Affects spermatogenesis	R
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Changes in morphology of seminiferous tubules
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Affects fertility
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Affects developmental process
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Affects testicular morphology
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Reduced sperm quality
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Changes in morphology of seminal vesicles
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Decreased estradiol levels
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Decreased progesterone levels
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Abnormal estrous cycles
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Affects ovarian follicles population
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Alterations in number of leydig cells
	IVR	1 - 5 mg/kg	1 - 5 mg/kg	Chang
	IVR	1 - 5 mg/kg	1 - 5 mg/kg
	IVR	1 - 5 mg/kg	1 - 5 mg/kg
	IVR	1 - 2 mg/kg	1 - 2 mg/kg
	IVR	1 - 5 mg/kg	1 - 5 mg/kg
	IVR	1 - 5 mg/kg	1 - 5 mg/kg
	IVR	1 - 5 mg/kg	1 - 5 mg/kg
	IVR	1 - 5 mg/kg	1 - 5 mg/kg
	IVR	1 - 8 mg/kg	1 - 8 mg/kg
	IVR	1 - 8 mg/kg	1 - 8 mg/kg
	IVR	1 - 8 mg/kg	1 - 8 mg/kg
	IVR	1 - 5 mg/kg	1 - 5 mg/kg
	IVR	1 - 8 mg/kg	1 - 8 mg/kg
	IVR	1 - 8 mg/kg	1 - 8 mg/kg
	IVR	mg/kg	-

---

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.